Lilly unlikely to prevail in cefaclor patent suit, court rules; preliminary injunction against Ivax, Lederle denied.
Executive Summary
LILLY "NOT LIKELY TO SUCCEED" IN CEFACLOR PATENT SUIT, COURT STATES in denying Lilly's request for a preliminary injunction against generic cefaclor marketing by Ivax, Biocraft and Lederle. The Indianapolis federal court denied Lilly's petition on Aug. 4. Lilly had requested a preliminary injunction to prevent the three firms from marketing a generic version of its antibiotic Ceclor as part of a patent infringement suit.